|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Masofaniten in Prostate Cancer Phase 1/2 Trial: Data and Future Directions
|
|
Christos Kyriakopoulos, MD
|
| Christos Kyriakopoulos discusses the phase 1/2 trial of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
|
INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer
|
|
Niven Mehra, MD, PhD
|
| Neeraj Agarwal interviews Niven Mehra about the INSPIRE trial. The study examines the efficacy of nivolumab and ipilimumab combination therapy in molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC).
|
|
|
|
|
|
|
|
|
|
|
|
|
Emerging DLL3-Targeted Therapies Demonstrate Efficacy in Neuroendocrine Prostate Cancer
|
|
Himisha Beltran, MD
|
| Himisha Beltran discuses DLL3, a promising target for neuroendocrine prostate cancer treatment. Dr. Beltran explains that DLL3 is highly expressed in neuroendocrine and small cell prostate cancers, making it an attractive therapeutic target.
|
|
|
|
|
|
|
|
|
|
|
|
| Radioligand Theranostics in Prostate Cancer: Status Quo and New Developments
|
| Ken Herrmann, MD
|
| PSMA can be visualized with PSMA-targeted radioligands that can be used for either PET imaging or therapeutic purposes. It is a transmembrane protein expressed on the surface of prostate cancer cells, with no appreciable circulation, and is highly expressed in prostate cancer cells within the tumor tissue (both primary and metastatic) in up to 80% of men with prostate cancer.
|
|
|
|
|
|
| The NEPI Trial: A Randomized Phase I/II Study of Neoadjuvant Treatment with 177-Lutetium-PSMA-617 with or without Ipilimumab in Patients with Very High-Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy
|
| Ulrich Krafft, MD
|
| Dr. Ulrich Krafft presented the trial design of the NEPI trial, a randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 (LuPSMA) with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy.
|
|
|
|
|
|
| The STAMPEDE2 Niraparib-Abiraterone Acetate + Prednisolone Trial: A Phase III, Randomized, Open-Label Trial in Patients with Metastatic Prostate Cancer with a Deleterious Alteration in a HRR Gene Starting ADT
|
| Sarah Howlett,, MD
|
| Sarah Howlett presented the trial design of STAMPEDE2, a phase 3, randomized, open-label trial of niraparib-abiraterone acetate + prednisolone in patients with metastatic prostate cancer with a deleterious alteration in a HRR gene starting ADT. Treatment intensification at the start of ADT improves overall survival in metastatic prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
| Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP)
|
| Savita Dandapani, MD, PhD
|
| Dr. Savita Dandapani presented the Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy, and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP).
|
|
|
|
|
|
| Efficacy and Safety of Darolutamide plus ADT in Patients with mHSPC from the Phase 3 ARANOTE Trial
|
| Fred Saad, MD, FRCSC
|
| Dr. Fred Saad presented the efficacy and safety of darolutamide plus ADT in patients with mHSPC from the phase 3 ARANOTE trial. In ARASENS, darolutamide + ADT + docetaxel significantly improved overall survival versus ADT + docetaxel in patients with mHSPC, and incidences of treatment-emergent adverse events were similar in both groups.
|
|
|
|
|
|
| Radium-223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Patients with Bone Metastatic Castration-Resistant Prostate Cancer: First Results of EORTC-GUCG 1333/PEACE-3
|
| Silke Gillessen Sommer, MD
|
| Professor Silke Gillessen presented the initial results of EORTC-GUCG 1333/PEACE-3, a phase III trial of radium-223 plus enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castrate-resistant prostate cancer (mCRPC).
|
|
|
|
|
|
|
|
